Trending NewsTrending NewsMost-Downgraded StocksMost-DowngradedNASDAQ:IONS Ionis Pharmaceuticals (IONS) Stock Price, News & Analysis $43.93 -1.82 (-3.98%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$44.38 +0.45 (+1.01%) As of 09/23/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ionis Pharmaceuticals Stock (NASDAQ:IONS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ionis Pharmaceuticals alerts:Sign Up Key Stats Today's Range$43.01▼$46.4150-Day Range$43.93▼$63.5752-Week Range$43.01▼$86.74Volume3.54 million shsAverage Volume3.84 million shsMarket Capitalization$7.30 billionP/E RatioN/ADividend YieldN/APrice Target$90.50Consensus RatingModerate Buy Company Overview Ionis Pharmaceuticals, Inc. is a biotechnology company that discovers and develops medicines using antisense technology, which is designed to target RNA and influence the production of disease-related proteins. The company focuses on neurological, cardiovascular, metabolic and other serious diseases for which there remains a significant unmet medical need. Ionis has developed several approved therapies, including SPINRAZA (nusinersen) for spinal muscular atrophy, QALSODY (tofersen) for a form of amyotrophic lateral sclerosis, TEGSEDI (inotersen) for hereditary transthyretin-mediated amyloidosis and WAYLIVRA (volanesorsen) for familial chylomicronemia syndrome in certain markets. Its pipeline also includes eplontersen, an antisense medicine developed with AstraZeneca for transthyretin amyloidosis. Founded in 1989, Ionis is headquartered in Carlsbad, California. The company develops medicines independently and through collaborations with pharmaceutical partners, supporting commercialization and distribution across international markets. Ionis is led by Chief Executive Officer Brett P. Monia.AI Generated. May Contain Errors. Read More Ionis Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreIONS MarketRank™: Ionis Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat, and ranked 303rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingIonis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 17 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialIonis Pharmaceuticals has a consensus price target of $90.50, representing about 106.0% upside from its current price of $43.93.Amount of Analyst CoverageIonis Pharmaceuticals has been the subject of 18 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ionis Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($3.57) to ($2.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is -12.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is -12.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 14.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ionis Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.82% of the float of Ionis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIonis Pharmaceuticals has a short interest ratio ("days to cover") of 9.18.Change versus previous monthShort interest in Ionis Pharmaceuticals has recently increased by 0.07%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.37 News SentimentIonis Pharmaceuticals has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Ionis Pharmaceuticals this week, compared to 9 articles on an average week.Search InterestOnly 18 people have searched for IONS on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Ionis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership2.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have sold 1,095.48% more of their company's stock than they have bought. Specifically, they have bought $1,058,700.00 in company stock and sold $12,656,566.00 in company stock.Percentage Held by Insiders1.81% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions93.86% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ionis Pharmaceuticals' insider trading history. Receive IONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IONS Stock News HeadlinesIonis Pharmaceuticals, Roche Say Kidney Disease Drug Candidate Meets Main Goal in Phase 3 Study4 hours ago | finance.yahoo.comIonis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney DiseaseSeptember 23 at 8:13 AM | benzinga.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. | Behind the Markets (Ad)Ionis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN)September 23 at 1:00 AM | businesswire.comIonis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALSSeptember 22 at 9:58 AM | marketscreener.comMOtsuka, Ionis' experimental ALS drug meets main goal in late-stage studySeptember 22 at 8:37 AM | reuters.comInvestors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish OutlookSeptember 20 at 9:30 AM | fool.comIonis Pharmaceuticals (IONS) Dropped, What Is Behind The Latest Attention?September 18, 2026 | finance.yahoo.comSee More Headlines IONS Stock Analysis - Frequently Asked Questions How have IONS shares performed this year? Ionis Pharmaceuticals' stock was trading at $79.11 at the start of the year. Since then, IONS stock has decreased by 44.5% and is now trading at $43.93. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) issued its quarterly earnings results on Wednesday, April, 29th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.29. Ionis Pharmaceuticals's revenue for the quarter was up 86.4% compared to the same quarter last year. Read the conference call transcript. Who are Ionis Pharmaceuticals' major shareholders? Top institutional investors of Ionis Pharmaceuticals include Alyeska Investment Group L.P. (0.85%), Bank of America Corp DE (0.48%), Connor Clark & Lunn Investment Management Ltd. (0.41%) and TimesSquare Capital Management LLC (0.37%). Insiders that own company stock include Brett P Monia, Spencer R Berthelsen, Elizabeth L Hougen, Eugene Schneider, C Frank Bennett, Brian Birchler, Patrick R O'neil, Richard S Geary, B Lynne Parshall, Joseph H Wender, Onaiza Cadoret-Manier, Michael R Hayden, Kyle Jenne, Holly B Kordasiewicz, Eric Swayze, Joseph Baroldi, Shannon L Devers, Joseph Klein III and Allene M Diaz. View institutional ownership trends. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ionis Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings4/29/2026Today9/23/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 IONS's financial health is in the Red zone, according to TradeSmith. IONS has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IONS CIK874015 Webwww.ionis.com Phone(760) 931-9200Fax760-603-2700Employees1,402Year Founded1989Price Target and Rating Average Price Target for Ionis Pharmaceuticals$90.50 High Price Target$129.00 Low Price Target$54.00 Potential Upside/Downside+106.0%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$381.39 million Net Margins-64.76% Pretax Margin-64.30% Return on Equity-111.08% Return on Assets-17.41% Debt Debt-to-Equity Ratio3.07 Current Ratio7.89 Quick Ratio7.73 Sales & Book Value Annual Sales$944 million Price / Sales7.73 Cash FlowN/A Price / Cash FlowN/A Book Value$3.02 per share Price / Book14.55Miscellaneous Outstanding Shares166,180,000Free Float163,176,000Market Cap$7.30 billion OptionableOptionable Beta0.42 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:IONS) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersElon gets it. Do you?Moderna's stock jumped nearly 200% in a single day after a successful Phase 3 trial for its cancer drug, and M...Porter & Company | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredA Scary Development Every AI Investor Needs to Take Note OfMicron surged over 500% in the past year, Intel climbed more than 250%, and AMD soared over 250% - but a $194 ...Weiss Ratings | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
